OBesity Surgery

Psychiatric needs must be considered

Increasing bariatric surgery for appropriate candidates could be cost effective and save the NHS and the wider community millions of pounds a year.1 However, such an increase may exacerbate the existing difficulties of obesity services in addressing the preoperative and postoperative psychiatric needs of patients having such surgery.

Many (50-80%) morbidly obese patients seeking bariatric surgery have a history of mental disorder, and psychiatric factors such as comorbid eating disorder and major depression seem to be better predictors of surgical outcome than biophysical variables.2,4 Hence, bariatric surgical services need to include integral psychiatric expertise preoperatively and postoperatively. Too often the process of assessing suitability for surgery is seen as akin to decision making before cosmetic surgery, rather than as an ongoing process.

Bariatric surgery itself may be regarded as a form of enforced behaviour therapy, and a successful outcome can require many years of psychiatric support in behaviour modification. Comprehensive care may sometimes be challenging, but we have found that candidates rarely receive the preoperative dietary, psychological, and psychiatric care required to successfully adapt to the required changes.

Patients also do not always receive close postoperative follow-up and support from a multidisciplinary team covering surgery, medicine, psychiatry/psychology, nutrition, and exercise science; optimally follow-up should be monthly for the first six months then every two months during the first year after surgery.2 Services addressing the preoperative and postoperative psychiatric needs of patients having bariatric surgery should be developed with consultation rather than as an afterthought. Obesity services need to consider screening for mental disorder, accessing specialist assessments, providing evidence based treatments, as well as integrating this treatment into the existing service to avoid false mind-body dualism.

William R Jones ST5 in psychiatry wjones79@yahoo.co.uk John F Morgan consultant psychiatrist and senior lecturer, Yorkshire Centre for Eating Disorders, Leeds LS14 6WB, UK

Competing interests: None declared.

1 McGauran A. More obesity surgery in England would be cost effective. BMJ 2010;341:c4915. (8 September.)

Cite this as: BMJ 2010;341:c5298

Big questions remain unanswered

Burns and colleagues provide a first and timely major observational study of bariatric surgery in the United Kingdom.1 They also draw welcome attention to the wide variation in surgical practice, which implies a gap in the evidence or that evidence is simply being ignored.

From a wider health service perspective, the importance of their study may be to highlight, once again, the limits of evidence and the need for long term controlled studies. The rapid growth of bariatric surgery, particularly in treating type 2 diabetes, is like a bandwagon, accelerating beyond its evidence base, with all the attendant dangers at the next bend in the road.2 Reliance on short term observational data, with the inherent biases and statistical limitations, is like a house built on sand. The place of the various different forms of bariatric surgery in medical practice, and in the wider NHS, will remain unresolved without a commitment to rigorous, long term comparative and controlled studies addressing an appropriate range of end points.

Jonathan H Pinkney professor of medicine, Peninsula College of Medicine and Dentistry, University Medicine level 7, Demdorff Hospital, Plymouth Hospitals NHS Trust, Plymouth PL6 0DH, UK jonathan.pinkney@pms.ac.uk

Competing interests: None declared.


Cite this as: BMJ 2010;341:c5304

SMoking v Obesity

Sedentary health strategy is illogical

It is illogical to place so much emphasis on obesity as a leading public health concern.1 Population attributable risks suggest that physical inactivity causes about 35% of coronary heart disease, 32% of colon cancer, and 35% of type 2 diabetes.2 In another study, population attributable risks for coronary heart disease were smoking 43%, saturated fatty acid intake 13%, obesity (body mass index >30) 14%, and sedentary lifestyle 40%.3

Increased physical activity reduces mortality by as much as smoking cessation, even in later life,4 and the comparative risk of obesity is not so clearly defined.

A recent BMJ poll suggested that when presented with the evidence most readers (83%) understand that health strategy should focus on increasing physical activity, rather than treating obesity. Many undesirable health risks are greatly reduced by physical activity and improved fitness, even in the absence of weight loss.5

To suggest smoking and obesity, rather than physical activity, have a comparable impact is dangerously misleading. All independent risk factors are important, but lack of physical activity and smoking are far greater public health threats than obesity.

Richard Weiler specialist registrar in sport and exercise medicine and general practitioner, Homer University Hospital NHS Trust, London E9 6SR, UK rweiler@doctors.org.uk

Competing interests: None declared.

1 Kamerow D. Smoking versus obesity: must we target only one? BMJ 2010;341:c4631. (24 August.)


Cite this as: BMJ 2010;341:c5292

Author’s reply

Weiler is of course correct that physical inactivity is a very strong risk factor for several diseases and for mortality.1 No one would argue otherwise. I chose to focus on comparing smoking with obesity in my column because that is where the funding seems to be going.

Similarly, no one would argue that obesity is not a pervasive health problem that needs attention. While increasing physical activity has positive effects independent of weight loss, most authorities would agree that we need population-wide changes in both diet and physical activity to prevent and treat obesity.

Douglas K Kamerow chief scientist, Health Services and Policy Research, RTI International, USA dkamerow@rti.org

Competing interests: None declared.


Cite this as: BMJ 2010;341:c5292

VEGETABLES AND DIABETES

Is nitrates the answer?

Carter and colleagues’2 systematic review and meta-analysis showed that a diet rich in green leafy vegetables but not fruit and vegetables or vegetables may confer protection against the risk of developing type 2 diabetes.3 They attribute this protective effect to the possible role of various antioxidants.

A diet rich in fruit and vegetables would be expected to increase consumption of these antioxidants, but it does not confer the same degree of protection as a diet rich in green leafy vegetables. A similar result was reported by Jae et al during a prospective study examining rates of cognitive decline.4 Again, green leafy vegetables were protective when other dietary components were not.

The green leafy vegetables described—for example, spinach, kale, and lettuce—differ from fruits and other vegetables in one important way—all have a high nitrate content. Nitrates from the diet have numerous beneficial physiological effects,5 including lowering blood pressure, improving endothelial function, and protecting against ischaemia reperfusion injury. Dietary nitrate is metabolised in humans to nitric oxide by sequential bacterial and chemical reduction,6 and may be able to restore the deficient levels that are postulated to mediate the genesis and consequences of type 2 diabetes.7

The protective effect seen in Carter and colleagues’ analysis may be a consequence of the vascular actions of nitrate from the diet.

Mark Gilchrist clinical research fellow mark.gilchrist@pms.ac.uk

Nigel Benjamin honorary professor of medicine, Diabetes and Vascular Medicine, Institute of Biomedical and Clinical Science, Peninsula College of Medicine and Dentistry, Exeter EX2 5AX, UK

Competing interests: NB is a cofounder of Heartbeet, a non-profit making organisation set up to promote the health benefits of dietary nitrate


Cite this as: BMJ 2010;341:c5306

BISPHOSPHONATES AND CANCER

More data using same database

Green and colleagues report the risk of various gastrointestinal cancers with oral bisphosphonates.1 Using a similar dataset from the same database, we independently compared bisphosphonate prescribing in cases of upper gastrointestinal cancer with that in controls from 1995 (when alendronate was first licensed) to 2007.

The odds of being a case increased 1.17 times for those taking bisphosphonates (odds ratio 1.17, 95% confidence interval 1.04 to 1.31). The effect was greater in women alone (1.29, 1.12 to 1.47) with no effect in men (0.95, 0.77 to 1.17).

We found a smaller effect than Green and colleagues, presumably because we combined oesophageal and gastric cancers. We did this to maximise the number of cases and because most of the increase in oesophageal cancer is adenocarcinoma, and lower oesophageal tumours and gastric tumours at the cardia may have a similar aetiology.

Indeed, Green and colleagues found the adjusted relative risks for one or more bisphosphonate prescriptions versus no prescription were 2.02 (1.02 to 4.01) for adenocarcinoma and 0.83 (0.36 to 1.93) for squamous cell carcinoma.

When we compared cases of oesophageal cancer and controls the odds of being a case increased to 1.24 (1.08 to 1.44), with a greater effect in women alone (1.40, 1.18 to 1.67) and no effect in men (0.97, 0.74 to 1.26). Green and colleagues found no effect of sex, which may be partly because women have been exposed to bisphosphonates for longer.

Our initial analysis suggests that 85 out of 4442 female cases of upper gastrointestinal cancer annually in the UK could be linked to bisphosphonate use.

Cardwell et al investigated the same question in a cohort design using the same database.2 We three research teams did not know about each other before publication. Is this common?

Ellen Wright clinical academic fellow, Department of Primary Care and Public Health Sciences, King’s College London, Capital House, London SE1 3QD, UK ellen.wright@kcl.ac.uk

Paul T Seed senior lecturer in medical statistics, King’s College London, Capital House, London SE1 3QD, UK

Peter Schofield research fellow Roger Jones emeritus professor of general practice, Department of Primary Care and Public Health Sciences, King’s College London, Capital House, London SE1 3QD, UK

Competing interests: None declared.


Cite this as: BMJ 2010;341:c5315

EFFICIENCY OF USER CHARGES

Reducing user fees often reduces supply of services

Thomson and colleagues’ analytical framework for understanding the impact of user fees is useful for developing countries.1 However, for developing countries with weak public delivery systems, user fees in public clinics are associated with higher output because of a mix of staff incentivisation and the production benefit of having the extra resources available in the clinic. To determine the effect of a reduction in user fees on the use of services in such settings, the impact of the decrease in supply for high and medium value services must also be taken into account. This supply reduction could potentially dominate the effect of the increase in demand resulting from the lower prices paid by users. The best way to
User charges require objective analysis

Thomson and colleagues explain how charges are being refined to reduce low value care in Europe but conclude that the UK does not need this strategy because it uses others. To reduce low value care, every effective strategy is needed.

User charges for prescriptions in the UK raise about £1bn (€1.17bn; $1.57bn) annually. The efficiency argument for such charges (using them instead of tax financing) is unjustified, but the resources that they generate should not be dismissed. If they stay, prescription charges should be reformed to avoid the need to claim exemptions. The current income limit is so low that adverse health impacts may occur in those with below average incomes. Moreover, prescriptions are initiated by doctors, so there is little justification for charging. So where else could £1bn be found?

Logically, user charges should be instituted for patient initiated direct access to primary care, including accident and emergency and GP attendances. From 1995 to 2008, the consultation rate per person year in general practice increased 32% from 3.88 to 5.45 (figure). GPs and other practice staff have increased, but more slowly. Accident and emergency attendances increased from 12.5 million to 18.8 million, and contacts with new NHS funded providers have also grown. Thomson and colleagues concede that a charge could remain for low value care but ask why provide it at all. Unless they are suggesting that walk-in primary care should cease, strategies—including carefully crafted user charges—are urgently needed to reduce low value attendances.

Michael A Soljak
postgraduate researcher, Department of Primary Care and Public Health, Imperial College London, London W6 8RP, UK m.soljak@imperial.ac.uk

Competing interests: None declared.

Cite this as: BMJ 2010;341:c5300

SHIFTS AND HANDOVERS

EWTD not responsible for near misses

In a two month period, 73 admissions after 5 pm were included in the Blackburn urology out of hours admissions audit. It is disappointing that such small numbers of patients were not handed over adequately, leading to near misses.

Suredly the threat to patient safety is a consequence of poor handover, poor tracking of out of hours admissions, and lack of senior input at night (on-site or by phone), rather than the shift system as the authors suggest.

Aldair I Moonie
acute physician, York Hospital, York, UK allymoonie@hotmail.com

Competing interests: None declared.

Cite this as: BMJ 2010;341:c5303

CARDIOVASCULAR RISK FROM DRUGS

What is an appropriate degree of risk?

In the light of her recent comments on rosiglitazone in the BMJ and the popular press, I wonder what Godlee would consider to be an appropriate degree of cardiovascular risk for any drug. The most recent data from the Office of National Statistics show that deaths related to the illicit use of cocaine have been steadily increasing in this country and reached 235 in 2008. Most of these deaths were in young men and from a cardiovascular cause.

Although no substantive data are available, it’s reasonable to assume that the illicit use of cocaine was also associated with a considerable number of non-fatal coronary events, quite possibly amounting to many times the number of recorded deaths as these events are likely to be under-reported. Caffeine use was also responsible for more than 3% of sudden deaths in southern Spain, the authors concluding that no level of use could be considered safe.

If this degree of cardiovascular risk were evident in a prescription drug it would be immediately withdrawn from the market, or at least subject to highly restrictive prescribing practices and vastly increased scrutiny. Why should this not also apply to a controlled drug when the same hazards to the “patient” are evident?

Rolls recently argued in the BMJ that cocaine and other “recreational” drugs should be made widely available to the general public through “specialist pharmacies,” and both Godlee and the outgoing president of the Royal College of Physicians have endorsed this proposal. But what method is to be used to establish the safety and reliability that ensure appropriate staffing and adequate supervision. It would have been helpful if the Blackburn study had analysed the reasons for the identified errors.

The EWTD led changes are relatively new. A transition period during which systems and working practices that are most suited to the new structure evolve is inevitable. Rather than throwing our hands in the air and harking back to the old way of working, which was dispensed with for good reason, we should focus on ensuring appropriate systems for the new way of working.

Aideen T O’Neill
foundation year 1 doctor, North Middlesex University Hospital NHS Trust, UK aideen.oneill@gmail.com

Competing interests: None declared.

Cite this as: BMJ 2010;341:c5320
and efficacy of these drugs in that setting if we are to ignore the requirements of the Medicines Act?

Godlee’s position on this issue is not consistent with the stance she has adopted on the safety of prescription pharmaceuticals in general.

Nigel J Keegan
medical practitioner, Newark,
Nottinghamshire NG24 1SG, UK nigelkeegan@aol.com

Competing interests: None declared.

4 Rolles S. An alternative to the war on drugs. BMJ 2010;341:c3160.
6 Top doctor Sir Ian Gilmore calls for drugs law review. 17 August. www.bbc.co.uk/news/health-10999921.

Cite this as: BMJ 2010;341:c5319

Widen the perspective

Caldwell’s points about the causes of avoidable harm to patients could be expanded and enhanced by a view from general practice.1 The pressure that Caldwell describes “to get patients out of hospital” results in them being deposited at home at no notice or short notice, occasionally to an empty house. One of my consultant colleagues was told recently by the hospital manager to do a ward round at 2200 to identify suitable patients to send home there and then because of a lack of beds for admissions accumulating in the accident and emergency department. Readmission of ill people sent home in such a way is common, necessary, and understandable and currently generates more revenue for the hospital trusts until the suggestions of Mr Lansley are implemented.

Caldwell gives examples of errors in working diagnoses caused by unavailability or disorganisation of notes. I observe that errors are also caused by a lack of continuity of care from the working arrangements imposed on doctors, and not merely the doctors in training. A discharge letter may be composed by the most junior member of the team who has never seen the patient. Frequently the consultant allegedly responsible for the patient has not supervised this discharge letter for detail and quality.

A useful means of arriving at a working diagnosis in hospital might be to contact the patient’s general practitioner for further information. This is seldom done, again to the detriment of the care of the patient.

Formal ward rounds with medical staff and nursing staff no longer exist in some hospitals.

Need I say more?

Michael G Bamber
general practitioner, Cotlesworth Medical Practice, Grantham NG33 5NL, UK mgbamber@nhs.net

Competing interests: None declared.

1 Caldwell G. What is the main cause of avoidable harm to patients? BMJ 2010;341:c4593. (9 September.)

Cite this as: BMJ 2010;341:c5323

Consider paternalism

Misdiagnosis can and does have disastrous consequences for patients and carers.1 However, risk management from Caldwell’s old fashioned, doctor centric standpoint means that equally valid opportunities to reduce avoidable risk are overlooked.

Patient centred clinicians are no less concerned with getting the diagnosis right but they insist that patients should be given the opportunity to be fully engaged in all the decisions that affect their health.2 Caldwell emphasises how difficult it is for healthcare professionals to make sensible decisions when they are in a rush, have incomplete and sometimes inaccurate facts, and are in uncomfortable surroundings. How much more difficult must it be for patients to give valid consent? At least doctors are working in a familiar environment and using language they understand.

In my experience, great harms are done inadvertently to patients by benign paternalists who genuinely believe that their decisions are more important than their patients.3 Cardiology has been the major beneficiary of the last administration’s “generosity” and has everything Caldwell asks for. Last year cardiologists performed around 50 000 palliative angioplasty procedures. COURAGE showed that most of these were avoidable and 8% were inappropriate.4 Over 16 000 of these patients sustained sufficient myocardial injury to increase mortality by 33%.5 Does anyone imagine for a moment that these patients knew when they gave their consent that angioplasty for stable angina is purely palliative; commonly causes irreversible harm; provides only a small temporary benefit; might be placebo; and could have been avoided by optimal conservative management? So much for avoiding harm by making the decision making process easier for clinicians.

GP commissioners beware. Paternalism is alive and well and has little time for the moral imperative of “No decision about me, without me.”

Michael R Chester
consultant cardiologist and director, National Refractory Angina Centre, Liverpool L4 3PE, UK info@angina.org

Competing interests: MRC acts as a patient-centred commissioning consultant.

1 Caldwell G. What is the main cause of avoidable harm to patients? BMJ 2010;341:c4593. (9 September.)
5 Cuculich F, Lim CCS, Banning AP. Proximal percutaneous myocardial injury during elective percutaneous coronary intervention: is it important and how can it be prevented? Heart 2010;96:736-40.

Cite this as: BMJ 2010;341:c5324